Evidence map›Paper›PMID 39786993›Full record

ArticleCell reports2025

Hydrogen sulfide mediates the interaction between C. elegans and Actinobacteria from its natural microbial environment.

Om Patange, Peter Breen, Giulia Arsuffi, Gary Ruvkun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Om PatangeDepartment of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
Peter BreenDepartment of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; Cell Biology and Physiology, School of Medicine, University of North Carolina, Chapel Hill, Chapel Hill, NC 27599, USA.
Giulia ArsuffiIndependent scholar, 00061 Anguillara Sabazia, RM, Italy.
Gary RuvkunDepartment of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA. Electronic address: ruvkun@molbio.mgh.harvard.edu.

Funding

CONTROL OF THE C ELEGANS LINEAGE BY HETEROCHRONIC GENESR01GM044619 · NIGMS · MASSACHUSETTS GENERAL HOSPITAL · PI GARY B RUVKUN · 1991 to 2026
$14.5M
GENETIC AND MOLECULAR BASIS OF LONGEVITYR01AG016636 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI GARY B RUVKUN · 1999 to 2026
$12.4M
NIA NIH HHS R01 AG016636NIGMS NIH HHS R01 GM044619
6 · The paper itself

Abstract

Caenorhabditis elegans proliferates poorly in the presence of abundant Actinobacteria from its natural ecology, but it is unknown why. Here, we show how perturbed levels of hydrogen sulfide modulate the growth rate of both C. elegans and Actinobacteria. From a forward genetic selection, we find C. elegans mutants with faster growth on an Actinobacteria Microbacterium species and mutant alleles of conserved cystathionine gamma-lyase (cth-2/CTH) that improve growth rate. Conversely, null alleles of cth-2 cause developmental arrest of animals grown on Actinobacteria, but not on Proteobacteria, which can be rescued by exogenous H

Indexed as

ActinobacteriaCaenorhabditis elegansHydrogen SulfideAnimalsCaenorhabditis elegans ProteinsCystathionine gamma-LyaseCysteineMutationCaenorhabditis elegans ProteinsCystathionine gamma-LyaseCysteineHydrogen SulfideActinobacteriacdo-1/CDO1C. elegansCP: Developmental biologyCP: Metabolismcth-2/CTHecologyH(2)Slrr-2/LRRC58

Identifiers

PMID39786993
PMCPMC13158863

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.